News

We would hope between now and 2030 to see a dramatic shift in how we treat and define disease." Now an adviser to the AI-based drug discovery and development company Immunai, Dolsten envisions a lab of the future "where science is integrated with medical practice almost in real time." Between industry firsts like Insilico Medicine's AI-designed pulmonary fibrosis candidate rentosertib and Google DeepMind's Nobel Prize-winning AlphaFold platform for three-dimensional protein mapping, the industry already can point to a few AI success stories. "Instead of hallucinating incorrect answers from a lack of information, AI models that are better at introspection would be able to say, 'I don't know,' or ask for further clarification." With Cradle's platform, a researcher starts with a target or a binder — or a wider library of binders — and builds a "plate" of potential outputs. The company is embarking on a new academic collaboration effort to provide immunology researchers with free access to the sequencing technology on an application basis — a program that will hopefully fill a gap left by cuts to the NIH — and serve to bulk up Amica's datasets. "We're looking for innovations to come out of this, not just through single-cell sequencing, but in the broader context of big scientific questions to pinpoint the convergence of technology, AI and clinical science and make a more significant leap forward in knowledge," Dolsten said."